DDrare: Database of Drug Development for Rare Diseases

Trifluoperazine (DrugBank: Trifluoperazine)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
283	後天性赤芽球癆	1
284	ダイアモンド・ブラックファン貧血	1

283. 後天性赤芽球癆　［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 17 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03966053 (ClinicalTrials.gov)	September 13, 2019	23/5/2019	The Use of Trifluoperazine in Transfusion Dependent DBA	Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia	Diamond Blackfan Anemia;Pure Red Cell Aplasia	Drug: Trifluoperazine	Adrianna Vlachos	NULL	Recruiting	18 Years	65 Years	All	24	Phase 1;Phase 2	United States

284. ダイアモンド・ブラックファン貧血　［臨床試験数：37，薬物数：110（DrugBank：34），標的遺伝子数：22，標的パスウェイ数：121］

Searched query = "Diamond-Blackfan anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 37 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03966053 (ClinicalTrials.gov)	September 13, 2019	23/5/2019	The Use of Trifluoperazine in Transfusion Dependent DBA	Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia	Diamond Blackfan Anemia;Pure Red Cell Aplasia	Drug: Trifluoperazine	Adrianna Vlachos	NULL	Recruiting	18 Years	65 Years	All	24	Phase 1;Phase 2	United States